Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Monopar Therapeutics (MNPR) Assets: 2016-2020

Historic Assets for Monopar Therapeutics (MNPR) over the last 3 years, with Sep 2020 value amounting to $18.2 million.

  • Monopar Therapeutics' Assets rose 255.40% to $18.2 million in Q3 2020 from the same period last year, while for Sep 2020 it was $18.2 million, marking a year-over-year increase of 255.40%. This contributed to the annual value of $13.4 million for FY2019, which is 82.46% up from last year.
  • According to the latest figures from Q3 2020, Monopar Therapeutics' Assets is $18.2 million, which was up 41.81% from $12.8 million recorded in Q2 2020.
  • In the past 5 years, Monopar Therapeutics' Assets ranged from a high of $18.2 million in Q3 2020 and a low of $2.9 million during Q4 2016.
  • Over the past 3 years, Monopar Therapeutics' median Assets value was $8.4 million (recorded in 2018), while the average stood at $9.7 million.
  • Its Assets has fluctuated over the past 5 years, first crashed by 35.23% in 2019, then surged by 255.40% in 2020.
  • Monopar Therapeutics' Assets (Quarterly) stood at $2.9 million in 2016, then soared by 242.98% to $9.9 million in 2017, then declined by 26.31% to $7.3 million in 2018, then spiked by 82.46% to $13.4 million in 2019, then spiked by 255.40% to $18.2 million in 2020.
  • Its last three reported values are $18.2 million in Q3 2020, $12.8 million for Q2 2020, and $12.8 million during Q1 2020.